Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer

Phase 2

• Conditions: Metastatic Breast Cancer

• Registration Number: NCT01451580
• Lead Sponsor: TTY Biopharm

Brief Summary

To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09
• Status Verified: 2011-10
• Study First Submitted: 2011-10-11
• Study First Submitted QC: 2011-10-12
• Last Update Submitted: 2011-10-12
• Study First Posted: 2011-10-13
• Last Update Posted: 2011-10-13

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

• histologically proved breast cancer with metastatic disease

Exclusion Criteria

• life expectancy less than 3 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

CGMH; 🇨🇳 Linko, Taiwan